12-Mar-2020 | Facts and Factors
Findings from Facts and Factors report “Efinaconazole Market By Type (Purity Above 98% and Purity Below 98%) and By Application (Onychomycosis and Other): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2020–2026” states that the global Efinaconazole market in 2019 was approximately USD 770 Million. The market is expected to grow at a CAGR of 3.2% and is anticipated to reach around USD 875 Million by 2026.
Efinaconazole is a drug widely used for fungal infection. They are used for certain types of infections such as toenail fungal infections. This drug is synthesized from a derivative of azole amine. The drug was first launched in Canada in the year of 2013 and in Japan in the year 2014 after the approval from their government. This drug is gaining its popularity in recent years owing to its safety profile and efficiency combined with the increased funding from government agencies and corporate industries. In addition, increasing awareness related to personal care and bolster in the pharmaceutical sector especially in the APAC region is projected to fuel the market’s growth. However, the oral consumption of this drug can cause liver toxicity, especially among the young and elderly population and long course for treatment may restrain the market’s growth during the forecast period. The rising awareness among the population globally about personal health care, more efficiency of Efinaconazole and the increased investment and innovation of the government and private agencies in healthcare is anticipated to create new avenues for the global Efinaconazole industry.
Browse the full “Efinaconazole Market By Type (Purity Above 98% and Purity Below 98%) and By Application (Onychomycosis and Other): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2020–2026" https://www.fnfresearch.com/efinaconazole-market-by-type-purity-above-98-and-720
On the basis of type, Efinaconazole with purity less than 98% dominated to the global market in 2019, owing to its above satisfactory results against toenail infection and its large base of end-users due to its less toxic nature. On the basis of application, Onychomycosis held the leading market share in 2019. The segment has witnessed a bolstering growth globally owing to its large patient base (approximately 50 million cases per year) and its chronic nature. On the basis of region, the North American region held the largest market share in 2019; this region was accounted for more than 48% share worldwide. The growth of this region is attributable to the presence of established pharmaceutical industries in this region, the growing awareness of personal healthcare among the population in this region and government investments in public healthcare.
Report Scope
Report Attribute |
Details |
Market Size in 2019 |
USD 770 Million |
Projected Market Size in 2026 |
USD 875 Million |
CAGR Growth Rate |
3.2% CAGR |
Base Year |
2019 |
Forecast Years |
2020-2026 |
Key Market Players |
Kaken Pharmaceutical Co., Ltd. ProcosS.p.A., Topharman CHEMVON BIOTECHNOLOGY (SHANGHAI) CO. LTD., TaizhouVolsen Chemical Co., Ltd., Valeant Pharmaceuticals International, Inc., Zhejiang Ausun Pharmaceutical Co., Ltd., Tenova Pharmaceuticals Inc., Viwit Pharmaceuticals Limited, RXN Chemicals Pvt. Ltd. , and others. |
Key Segment |
By Type , Application, and Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East &, Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
Some of the essential players operating in the Efinaconazole market, but not restricted to include Kaken Pharmaceutical Co., Ltd. ProcosS.p.A., Topharman CHEMVON BIOTECHNOLOGY (SHANGHAI) CO. LTD., TaizhouVolsen Chemical Co., Ltd., Valeant Pharmaceuticals International, Inc., Zhejiang Ausun Pharmaceutical Co., Ltd., Tenova Pharmaceuticals Inc., Viwit Pharmaceuticals Limited, RXN Chemicals Pvt. Ltd., and others.
This report segments the Efinaconazole market as follows:
GlobalEfinaconazole Market: By Type Segmentation Analysis
- Purity Above 98%
- Purity Below 98%
Global Efinaconazole Market: By Application Segmentation Analysis
Global Efinaconazole Market: Regional Segmentation Analysis
- North America
- Europe
- Germany
- The UK
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Contact Us:
Facts & Factors
A - 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: [email protected]
Web: https://www.fnfresearch.com
